PolyTherics Raises £3 million to Commercialise PEGylationTechnologies
Since commencement of operations in 2002, PolyTherics has developed a suite of technologies to improve the properties of biologics for therapeutic use. Having successfully out-licensed its targeted PEGylation technology TheraPEG™ to several commercial partners, the Company intends to use these new funds to exemplify its PEGylation platforms, HiPEG™ and CyPEG in the context of novel peptides and proteins as potential ‘biobetter’ products. PolyTherics intends to continue to out-license its PEGylation technologies while seeking external grants to support its research.
Robert Bahns of Imperial Innovations joins the Board of PolyTherics at this investment round, while Till Medinger and Stephane Mery resign from their non-executive director positions.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.